Figure 6.

Validation of proteomic data and characterization of androgen receptor (AR) and $\text{estrogen}\text{receptor}\left(\text{ER}\right)\mathrm{\alpha }$ expression in the medial preoptic nucleus (MPN). (A) 3-D view of the spot ID:0656, corresponding to GFAP, shown for three animals exposed to the vehicle (Veh) or DEHP at 5 or $50\mathrm{\mu }\mathrm{g}/\mathrm{kg}/\mathrm{d}$. (B–C) Upper panels: Representative Western blots of GFAP (B), $\mathrm{\beta }-\text{actin}$ (C), and GAPDH used as a protein reference, in the MPN of the Veh, DEHP-5, and DEHP-50 groups. Lower panels: quantification of the protein levels normalized to GAPDH. Data are expressed as the means $\pm \mathrm{SEM}$ of four males per treatment group, *$p<0.05$ compared to the vehicle group. (D–F) Representative AR-immunolabeling of the medial preoptic nucleus of males exposed to the vehicle (Veh) and DEHP at 5 or $50\mathrm{\mu }\mathrm{g}/\mathrm{kg}/\mathrm{d}$ (D) and quantitative data for AR- (E) and $\text{ER}\mathrm{\alpha }-\text{immunoreactive}$ cells (F). 3V: Third ventricle. Data are expressed as the means $\pm \mathrm{SEM}$ of four to six males per treatment group, *$p<0.05$ vs. the vehicle group. (G) AR gene expression in males exposed to the vehicle and DEHP at 5 or $50\mathrm{\mu }\mathrm{g}/\mathrm{kg}/\mathrm{d}$. Data are expressed as the means $\pm \mathrm{SEM}$ of six to eight males per treatment group, *$p<0.05$ compared to the vehicle group.